9 results about "Molecular Profile" patented technology

The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.

The invention relates to the technical field of medical data communication, in particular to a tumor treatment path dynamic optimization method and system, and the method comprises the steps: collecting a tumor tissue sample, and obtaining an integrated molecular spectrum of a tumor patient; performing multi-modal decision analysis on the integrated molecular spectrum to generate a multi-dimensional treatment strategy including a targeted treatment decision and an immunotherapy decision; constructing an individualized treatment path comprising a current treatment node and at least one future evolution node according to the multi-dimensional treatment strategy; physiological change data of the tumor patient is continuously monitored, and the continuity weight of each future evolution node is calculated based on the physiological change data; and sequencing the future evolution nodes according to the continuity weight and generating a new individualized treatment path based on the current treatment node. According to the invention, the core problem that the existing tumor treatment scheme cannot respond to the dynamic evolution of the tumor in real time due to static single detection is effectively solved, and the self-adaptive optimization of the treatment path along with the disease progress is realized.

A method for predicting properties of a product having alternative ingredients, the method comprising: receiving data of an ingredient profile of a product, a molecular profile associated with the ingredient profile, and a proportioning profile of the product based on the ingredient profile; determining a set of molecular descriptors for the product based on the molecular profile; determining a set of material descriptors for the product based on the set of molecular descriptors; determining a set of proportioning descriptors for the product based on the set of material descriptors and the proportioning profile; generating a measured set of functional properties of the product using a machine learning model based on the one or more proportioning descriptors; receiving one or more alternative ingredients of the product; and generating a predicted set of functional properties of the product by using the machine learning model based on the one or more alternative components.

Methods and systems for determining recurrence of a tumor in a subject using mutational profiles derived from cell-free DNA obtained concurrently with or prior to tumor resection and integrating mutational profiles from the resected tumor to enhance classification models. Low-depth whole-genome sequencing data can be used to obtain a variety of molecular profiles, including genetic and epigenetic profiles, from tumor tissue and blood samples obtained after the tumor is resected from the subject. The methods may also comprise using a classifier trained to recognize mutational profiles from subjects exhibiting minimal residual disease (MRD) to determine whether a tumor recurred in a subject.

The present invention provides an innovative analytical strategy specifically designed to overcome the inherent limitations of traditional ADME (absorption, distribution, metabolism, excretion) approaches in the pharmacokinetic and pharmacodynamic characterization of natural matrix-based therapeutic or beneficial products, such as products comprising or consisting of multi-component plant extracts. The present invention provides a fundamentally different approach that is not based on the molecular profile of an administered therapeutic or beneficial product. This novel approach relies on a methodology that captures the integrated functional response of an organism to the administration of a therapeutic or beneficial product, i.e., characterizes the pharmacokinetic and pharmacodynamic behavior of a therapeutic or beneficial product through a functional target response, independent of its chemical composition. The approach is applicable to conventional drugs and beneficial products, but is particularly suited to multi-component products, such as those containing natural matrices.

Disclosed herein are methods and systems for classifying a cancer from a subject. The methods and systems classify the cancer based on similar characteristics, e.g., molecular profiles. The methods and systems may be predictive of the subject's response to treatments based on the classification of the cancer. The methods and systems may be used to define improved therapies for subjects with cancers with limited treatment options, e.g., rare cancers.

Netherton syndrome (NS) is a rare recessive skin disorder caused by loss-of-function mutations in SPINK5 encoding the protease inhibitor LEKTI. NS patients present with typical ichthyosis linearis circumflexa (NS-ILC) or scaly erythroderma (NS-SE). Here the inventors employed a combination of several molecular profiling methods to comprehensively characterize the skin, immune cells and allergic phenotypes of NS-ILC and NS-SE patients. In particular, they studied a cohort of 13 NS patients comprising 9 NS-ILC and 4 NS-SE. Integrated multi-omics revealed abnormal epidermal proliferation and differentiation and IL-17 / IL-36 signatures in lesion skin and in blood in both NS endotypes. This study thus identifies IL-17 / IL-36 as predominant signaling axes in both NS endotypes and unveils molecular features distinguishing NS-ILC and NS-SE. In particular, blocking of IL36 signaling would therefore represent a novel therapeutic strategy for NS, in particular in NS-SE patients.

The present invention relates to compositions, kits, and methods for molecular profiling and cancer diagnostics, including but not limited to genomic DNA markers associated with cancer. In particular, the present invention provides molecular profiles associated with thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.

Provided herein are methods, compositions, kits, and systems for detecting Epstein Barr virus infection (EBV) in gastric cancer (GC) patients. In particular, provided herein are methods, composition, kits, and systems for diagnosing and treating EBV-positive gastric cancer (EBV+ GC) in a biological sample of an individual based on the presence and level of antibodies against particular Epstein Barr virus proteins. EBV+ GC is a distinct subtype of gastric cancer and is associated with unique molecular profiles. Also provided herein are methods for providing more personalized therapy for each of these distinct cancer subtypes and methods for determining an Epstein Barr virus-positive gastric cancer antibody signature, and kits comprising components and protocols for performing the methods of this disclosure.